Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early immune response comparison of bivalent versus nonavalent HPV vaccination
NL-OMON48227Phase 4Active, not recruiting
- Sponsor
- National Institute for Public Health and the Environment
- Start
- Jun 2019
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of human papillomavirus type 16 L1 capsid protein antigen and recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection (2 arms), sponsored by National Institute for Public Health and the Environment. Started Jun 2019; status: active, not recruiting.
02
Drugs
human papillomavirus type 16 L1 capsid protein antigenrecombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NL-OMON48227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48227.